Estimation of the impact of noncompliance on pharmacokinetics: An analysis of the influence of dosing regimens

British Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2008, Pages 871-878

  Hughes, Dyfrig A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Compliance; Oxybutynin; Pharmacokinetics; Risperidone

Indexed keywords

OXYBUTYNIN; RISPERIDONE;

ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXPOSURE; MULTIPLE DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STOCHASTIC MODEL;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MANDELIC ACIDS; MODELS, BIOLOGICAL; PARASYMPATHOLYTICS; PATIENT COMPLIANCE; RISPERIDONE; STATISTICS AS TOPIC; TIME FACTORS;

EID: 43549119732     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03124.x     Document Type: Article

References (41)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353: 487 97.
2. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23: 1296 310.
3. Hughes D. Less is more: medicines that require less frequent administration improve adherence, but are they better? Pharmacoeconomics 2006 24: 211 3.
4. Comte L, Vrijens B, Tousset E, Gerard P, Urquhart J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007 34: 549 58.
5. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998 33: 207 19.
6. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999 39: 289 96.
7. Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001 52: 409 17.
8. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003 160: 1125 32.
9. Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 2005 31 (5 Pt 1 609 15.
10. Huang ML, Rasmussen M, Woestenborghs R, Delor I, Van Peer A, Lowenthal R. Steady-state bioavailability in chronic schizophrenic patients comparing once daily oral administration of risperidone with intramuscular injections of a risperidone depot microspheres formulation given every two weeks. RIS-INT-32. Janssen Research Foundation, Clinical Research Report, February 2000. N137257.
11. Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG, Woo JI. Pharmacokinetic-pharmacodynamic modelling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology 1999 144: 272 8.
12. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994 55 (Suppl. 13 7.
13. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004 70: 91 100.
14. Pitsiu M, Sathyan G, Gupta S, Verotta D. A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin. J Pharm Sci 2001 90: 702 12.
15. Preik M, Albrecht D, O'Connell M, Hampel C, Anderson R. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU Int 2004 94: 821 7.
16. Hughes DA, Walley T. Predicting 'real world' effectiveness by integrating adherence with pharmacodynamic modeling. Clin Pharmacol Ther 2003 74: 1 8.
17. Girard P, Blaschke TF, Kastrissios H, Sheiner LB. A Markov mixed effect regression model for drug compliance. Stat Med 1998 17: 2313 33.
18. Wong D, Modi R, Ramanathan M. Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet 2003 42: 193 204.
19. Kenna LA, Labbé L, Barrett JS, Pfister M. Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J 2005 7: E390 407.
20. Sparr LF, Moffitt MC, Ward MF. Missed psychiatric appointments: who returns and who stays away. Am J Psychiatry 1993 150: 801 5.
21. Boissel J-P, Nony P. Using pharmacokinetic- pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet 2002 41: 1 6.
22. Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, Woods SW. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001 26: 325 9.
23. Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007 90: 229 37.
24. Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006 32: 724 42.
25. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999 161: 1809 12.
26. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005 15: 111 7.
27. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001 62: 282 9.
28. Gupta SK, Sathyan G, Lindemulder EA, Ho PL, Sheiner LB, Aarons L. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther 1999 65: 672 84.
29. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002 7: 317 21.
30. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 2004 7: 19 26.
31. Gefvert O, Eriksson B, Persson P, Helldin L, Björner A, Mannaert E, Remmerie B, Eerdekens M, Nyberg S. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005 8: 27 36.
32. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994 114: 9 23.
33. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 157: 1093 7.
34. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003 64 (Suppl. 16 18 23.
35. Nony P, Cucherat M, Boissel J-P. Revisiting the effect compartment through timing errors in drug administration. Trends Pharmacol Sci 1998 19: 49 54.
36. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992 22: 238 46.
37. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005 45: 461 7.
38. Levy G, Zamacona MK, Jusko WJ. Developing compliance instructions for labelling. Clin Pharmacol Ther 2000 68: 586 91.
39. Blesius A, Chabaud S, Cucherat M, Mismetti P, Boissel JP, Nony P. Compliance-guided therapy: a new insight into the potential role of clinical pharmacologists. Clin Pharmacokinet 2006 45: 95 104.
40. Vrijens B, Goetghebeur E, de Klerk E, Rode R, Mayer S, Urquhart J. Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 2005 24: 2719 31.
41. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003 25: 2307 35.